Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16791848,clearance (CL),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),[ml] / [min],1.2,5406,DB00557,Hydroxyzine
,16791848,clearance (CL),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),[ml] / [min],2.7,5407,DB00557,Hydroxyzine
,16791848,volume of distribution at steady state (Vss),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),ml,457,5408,DB00557,Hydroxyzine
,16791848,volume of distribution at steady state (Vss),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),ml,996,5409,DB00557,Hydroxyzine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,7-10,5410,DB00557,Hydroxyzine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,16-21,5411,DB00557,Hydroxyzine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,8,5412,DB00557,Hydroxyzine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,12,5413,DB00557,Hydroxyzine
,17581764,trough plasma concentration,"After three consecutive administrations of cetirizine (0.2 mg/kg body weight, bw) every 12h, the trough plasma concentration of cetirizine was 16+/-4 ng/mL (mean+/-SD) and the wheal formation was inhibited by 45+/-23%.",Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),[ng] / [ml],16,9715,DB00557,Hydroxyzine
,17581764,trough plasma concentration,"After four additional administrations of cetirizine (0.4 mg/kg bw) every 12 h, the trough plasma concentration was 48+/-15 ng/mL and the wheal formation was inhibited by 68+/-11%.",Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),[ng] / [ml],48,9716,DB00557,Hydroxyzine
,17581764,terminal half-life,The terminal half-life was about 5.8 h.,Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),h,5.8,9717,DB00557,Hydroxyzine
,17581764,EC(50),A pharmacokinetic/pharmacodynamic link model showed that the maximal inhibition of wheal formation was about 95% and the EC(50) about 18 ng/mL.,Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),[ng] / [ml],18,9718,DB00557,Hydroxyzine
,16083790,peak levocetirizine concentration,"In children aged 8.6 +/- 0.4 years (+/- SEM), the peak levocetirizine concentration was 450 +/- 37 ng/mL, and the time at which peak concentrations occurred was 1.2 +/- 0.2 hours.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),[ng] / [ml],450,24318,DB00557,Hydroxyzine
,16083790,time at which peak concentrations occurred,"In children aged 8.6 +/- 0.4 years (+/- SEM), the peak levocetirizine concentration was 450 +/- 37 ng/mL, and the time at which peak concentrations occurred was 1.2 +/- 0.2 hours.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),h,1.2,24319,DB00557,Hydroxyzine
,16083790,terminal elimination half-life,"The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),h,5.7,24320,DB00557,Hydroxyzine
,16083790,oral clearance,"The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),[ml] / [kg·min],0.82,24321,DB00557,Hydroxyzine
,16083790,volume of distribution,"The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),[l] / [kg],0.4,24322,DB00557,Hydroxyzine
,16083790,maximum inhibition,"Mean maximum inhibition of wheals and flares occurred from 2 to 10 hours (97% +/- 1%) and from 2 to 24 hours (93% +/- 1%), respectively.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),%,97,24323,DB00557,Hydroxyzine
,16083790,maximum inhibition,"Mean maximum inhibition of wheals and flares occurred from 2 to 10 hours (97% +/- 1%) and from 2 to 24 hours (93% +/- 1%), respectively.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),%,93,24324,DB00557,Hydroxyzine
,9158881,AUC ratios,"The AUC ratios between CSF and plasma for hydroxyzine after intranasal and intra-arterial administration were 4.0 and 0.4, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,4.0,27318,DB00557,Hydroxyzine
,9158881,AUC ratios,"The AUC ratios between CSF and plasma for hydroxyzine after intranasal and intra-arterial administration were 4.0 and 0.4, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.4,27319,DB00557,Hydroxyzine
,9158881,AUC ratios,"The AUC ratios for triprolidine, the other antihistamine with measurable CSF concentrations, were 0.5 and 0.7, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.5,27320,DB00557,Hydroxyzine
,9158881,AUC ratios,"The AUC ratios for triprolidine, the other antihistamine with measurable CSF concentrations, were 0.5 and 0.7, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.7,27321,DB00557,Hydroxyzine
,6361228,peak serum hydroxyzine concentration,"After a single 0.7 mg/kg orally administered dose of the drug, the mean peak serum hydroxyzine concentration of 47.4 +/- 17.3 ng/ml occurred at a mean time of 2.0 +/- 0.9 hours.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),[ng] / [ml],47.4,27785,DB00557,Hydroxyzine
,6361228,mean time,"After a single 0.7 mg/kg orally administered dose of the drug, the mean peak serum hydroxyzine concentration of 47.4 +/- 17.3 ng/ml occurred at a mean time of 2.0 +/- 0.9 hours.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),h,2.0,27786,DB00557,Hydroxyzine
,6361228,elimination half-life,"The mean elimination half-life was 7.1 +/- 2.3 hours, the mean clearance rate was 32.08 +/- 11.05 ml/min/kg, and the mean apparent volume of distribution was 18.5 +/- 8.6 L/kg.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),h,7.1,27787,DB00557,Hydroxyzine
,6361228,clearance rate,"The mean elimination half-life was 7.1 +/- 2.3 hours, the mean clearance rate was 32.08 +/- 11.05 ml/min/kg, and the mean apparent volume of distribution was 18.5 +/- 8.6 L/kg.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),[ml] / [kg·min],32.08,27788,DB00557,Hydroxyzine
,6361228,apparent volume of distribution,"The mean elimination half-life was 7.1 +/- 2.3 hours, the mean clearance rate was 32.08 +/- 11.05 ml/min/kg, and the mean apparent volume of distribution was 18.5 +/- 8.6 L/kg.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),[l] / [kg],18.5,27789,DB00557,Hydroxyzine
,8227463,elimination t1/2,The elimination t1/2 was prolonged in patients (mean +/- standard deviation; group A: 14.32 +/- 2.30 hours; group B: 13.86 +/- 3.14 hours) in comparison with the values observed in volunteers (9.42 +/- 2.4 hours).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),h,14.32,37088,DB00557,Hydroxyzine
,8227463,elimination t1/2,The elimination t1/2 was prolonged in patients (mean +/- standard deviation; group A: 14.32 +/- 2.30 hours; group B: 13.86 +/- 3.14 hours) in comparison with the values observed in volunteers (9.42 +/- 2.4 hours).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),h,13.86,37089,DB00557,Hydroxyzine
,8227463,elimination t1/2,The elimination t1/2 was prolonged in patients (mean +/- standard deviation; group A: 14.32 +/- 2.30 hours; group B: 13.86 +/- 3.14 hours) in comparison with the values observed in volunteers (9.42 +/- 2.4 hours).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),h,9.42,37090,DB00557,Hydroxyzine
,8227463,apparent oral body clearance,A reduced apparent oral body clearance also was observed in patients (group A: .48 +/- .23 mL/min/kg; group B: .41 +/- .09 mL/min/kg) in comparison with volunteers (.74 +/- .19 mL/min/kg).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),[ml] / [kg·min],.48,37091,DB00557,Hydroxyzine
,8227463,apparent oral body clearance,A reduced apparent oral body clearance also was observed in patients (group A: .48 +/- .23 mL/min/kg; group B: .41 +/- .09 mL/min/kg) in comparison with volunteers (.74 +/- .19 mL/min/kg).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),[ml] / [kg·min],.41,37092,DB00557,Hydroxyzine
,8227463,apparent oral body clearance,A reduced apparent oral body clearance also was observed in patients (group A: .48 +/- .23 mL/min/kg; group B: .41 +/- .09 mL/min/kg) in comparison with volunteers (.74 +/- .19 mL/min/kg).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),[ml] / [kg·min],.74,37093,DB00557,Hydroxyzine
,8227463,cumulative urinary excretion,No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 +/- 15%; group B: 69 +/- 13%) and volunteers (70.7 +/- 7.8%).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),%,69,37094,DB00557,Hydroxyzine
,8227463,cumulative urinary excretion,No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 +/- 15%; group B: 69 +/- 13%) and volunteers (70.7 +/- 7.8%).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),%,69,37095,DB00557,Hydroxyzine
,8227463,cumulative urinary excretion,No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 +/- 15%; group B: 69 +/- 13%) and volunteers (70.7 +/- 7.8%).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),%,70.7,37096,DB00557,Hydroxyzine
,30477556,plasma terminal half-life,Median (range) cetirizine plasma terminal half-life was 10 h (7.9-16.5).,Cetirizine per os: exposure and antihistamine effect in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30477556/),h,10,42372,DB00557,Hydroxyzine
,30477556,IC50,The median (range) IC50-value for reduction in wheal area was 0.33 µg/mL (0.07-0.45).,Cetirizine per os: exposure and antihistamine effect in the dog. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30477556/),[μg] / [ml],0.33,42373,DB00557,Hydroxyzine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,90.6,43480,DB00557,Hydroxyzine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,89.0,43481,DB00557,Hydroxyzine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,98.0,43482,DB00557,Hydroxyzine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,94.0,43483,DB00557,Hydroxyzine
,15490489,AUC,"The plasma cetirizine AUC of 201+/-24.2 ng.h/ml from SUV was lower than from PC-MLV, 334.6+/-65.1 ng.h/ml and from GB, 248.3+/-34.6 ng.h/ml.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),[h·ng] / [ml],201,43484,DB00557,Hydroxyzine
,15490489,AUC,"The plasma cetirizine AUC of 201+/-24.2 ng.h/ml from SUV was lower than from PC-MLV, 334.6+/-65.1 ng.h/ml and from GB, 248.3+/-34.6 ng.h/ml.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),[h·ng] / [ml],334.6,43485,DB00557,Hydroxyzine
,15490489,AUC,"The plasma cetirizine AUC of 201+/-24.2 ng.h/ml from SUV was lower than from PC-MLV, 334.6+/-65.1 ng.h/ml and from GB, 248.3+/-34.6 ng.h/ml.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),[h·ng] / [ml],248.3,43486,DB00557,Hydroxyzine
,15787865,volume of distribution,"The population PK model used predicted that with increasing body weight, levocetirizine oral clearance would increase by 0.044 l/h/kg, and levocetirizine volume of distribution would increase by 0.639 l/kg.",Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787865/),,0,45292,DB00557,Hydroxyzine
,12584158,efflux ratio,"Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.",P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584158/),,1,47722,DB00557,Hydroxyzine
,2892447,peak mean concentration,The drug was rapidly absorbed: The peak mean concentration of radioactivity (359 ng-equivalents/mL) and of unchanged drug (341 ng/mL) were achieved within one hour.,The metabolism and pharmacokinetics of 14C-cetirizine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892447/),[ng-equivalents] / [ml],359,52260,DB00557,Hydroxyzine
,2892447,peak mean concentration,The drug was rapidly absorbed: The peak mean concentration of radioactivity (359 ng-equivalents/mL) and of unchanged drug (341 ng/mL) were achieved within one hour.,The metabolism and pharmacokinetics of 14C-cetirizine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892447/),[ng] / [ml],341,52261,DB00557,Hydroxyzine
,2892447,elimination half-life,Mean concentrations of cetirizine declined biexponentially and had a mean elimination half-life of 7.4 hours.,The metabolism and pharmacokinetics of 14C-cetirizine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892447/),h,7.4,52262,DB00557,Hydroxyzine
,15198516,maximum suppression,"Mean maximum suppression, 85% to 94%, occurred from 2 to 6 hours, with no differences among the formulations.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),%,85,53490,DB00557,Hydroxyzine
,15198516,maximum suppression,"Mean maximum suppression, 85% to 94%, occurred from 2 to 6 hours, with no differences among the formulations.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),%,94,53491,DB00557,Hydroxyzine
,15198516,areas of plasma hydroxyzine concentration versus time area under the curve (AUCs),"The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1 +/- 20.8 and 78.4 +/- 33.9 ng/mL/h, respectively, were lower than that from GB, 492 +/- 141 ng/mL/h (P < or =.05) over 24 hours.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],80.1,53492,DB00557,Hydroxyzine
,15198516,areas of plasma hydroxyzine concentration versus time area under the curve (AUCs),"The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1 +/- 20.8 and 78.4 +/- 33.9 ng/mL/h, respectively, were lower than that from GB, 492 +/- 141 ng/mL/h (P < or =.05) over 24 hours.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],78.4,53493,DB00557,Hydroxyzine
,15198516,areas of plasma hydroxyzine concentration versus time area under the curve (AUCs),"The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1 +/- 20.8 and 78.4 +/- 33.9 ng/mL/h, respectively, were lower than that from GB, 492 +/- 141 ng/mL/h (P < or =.05) over 24 hours.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],492,53494,DB00557,Hydroxyzine
,15198516,AUCs,"Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765 +/- 50, 1035 +/- 202, and 957 +/- 227 ng/mL/h, respectively (P < or =.05).",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],765,53495,DB00557,Hydroxyzine
,15198516,AUCs,"Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765 +/- 50, 1035 +/- 202, and 957 +/- 227 ng/mL/h, respectively (P < or =.05).",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],1035,53496,DB00557,Hydroxyzine
,15198516,AUCs,"Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765 +/- 50, 1035 +/- 202, and 957 +/- 227 ng/mL/h, respectively (P < or =.05).",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],957,53497,DB00557,Hydroxyzine
,11528239,Basal levels,Basal levels of cetirizine in HD patients were confirmed to be 0 ng/ml.,Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11528239/),,0,54956,DB00557,Hydroxyzine
,10435475,peak values,Plasma cetirizine levels increased within 30 min to reach peak values of 315+/-10 and 786+/-45 ng/ml 90-120 min after administration of 10 and 20 mg of cetirizine.,Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435475/),[ng] / [ml],315,66340,DB00557,Hydroxyzine
,10435475,peak values,Plasma cetirizine levels increased within 30 min to reach peak values of 315+/-10 and 786+/-45 ng/ml 90-120 min after administration of 10 and 20 mg of cetirizine.,Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435475/),[ng] / [ml],786,66341,DB00557,Hydroxyzine
,10435475,In vivo recovery,In vivo recovery of cetirizine was 14.4+/-4.3%.,Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435475/),%,14.4,66342,DB00557,Hydroxyzine
,512901,peak plasma concentrations,"Following administration of 100-mg single oral doses to normal male volunteers, peak plasma concentrations of approximately 80 ng/ml were observed; the half-life of drug removal was approximately 3 hr.",Sensitive assay for determination of hydroxyzine in plasma and its human pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512901/),[ng] / [ml],80,78955,DB00557,Hydroxyzine
,512901,half-life of drug removal,"Following administration of 100-mg single oral doses to normal male volunteers, peak plasma concentrations of approximately 80 ng/ml were observed; the half-life of drug removal was approximately 3 hr.",Sensitive assay for determination of hydroxyzine in plasma and its human pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512901/),h,3,78956,DB00557,Hydroxyzine
,7897151,area under the curve,"When hydroxyzine was administered with cimetidine, the partial hydroxyzine area under the curve increased significantly (p < 0.05) to 303 +/- 92 ng/ml/hr from 227 +/- 77 ng/ml/hr after administration of hydroxyzine alone, and the concentration of cetirizine arising from hydroxyzine was lower.",Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7897151/),[ng] / [h·ml],303,87715,DB00557,Hydroxyzine
,7897151,area under the curve,"When hydroxyzine was administered with cimetidine, the partial hydroxyzine area under the curve increased significantly (p < 0.05) to 303 +/- 92 ng/ml/hr from 227 +/- 77 ng/ml/hr after administration of hydroxyzine alone, and the concentration of cetirizine arising from hydroxyzine was lower.",Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7897151/),[ng] / [h·ml],227,87716,DB00557,Hydroxyzine
,15606437,CL/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[l] / [h],0.60,93395,DB00557,Hydroxyzine
,15606437,CL/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[l] / [h],1.13,93396,DB00557,Hydroxyzine
,15606437,V/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),l,5.1,93397,DB00557,Hydroxyzine
,15606437,V/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),l,12.8,93398,DB00557,Hydroxyzine
,15606437,relative bioavailability,The estimated relative bioavailability was 0.28 in 12% of instances of suspected noncompliance.,Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),,0.28,93399,DB00557,Hydroxyzine
,15606437,AUC(ss),"AUC(ss), calculated in compliant subjects using posterior estimates of the final model, was 1952 (1227-3319) microg l(-1) h (mean, min-max), a value similar to that in adults after intake of 5 mg oral solution (2036 (1414-2827) microg l(-1) h.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[h·μg] / [l],1952,93400,DB00557,Hydroxyzine
,15606437,AUC(ss),"AUC(ss), calculated in compliant subjects using posterior estimates of the final model, was 1952 (1227-3319) microg l(-1) h (mean, min-max), a value similar to that in adults after intake of 5 mg oral solution (2036 (1414-2827) microg l(-1) h.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[h·μg] / [l],2036,93401,DB00557,Hydroxyzine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.34,96056,DB00557,Hydroxyzine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.40 to 0.60,96057,DB00557,Hydroxyzine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.25,96058,DB00557,Hydroxyzine
,2866055,Total body clearance,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[ml] / [kg·min],5 to 12,96059,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,3,96060,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18,96061,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,4,96062,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,10 to 14,96063,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,14 to 25,96064,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,20,96065,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,25,96066,DB00557,Hydroxyzine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18 to 20,96067,DB00557,Hydroxyzine
excess,2866055,apparent volumes of distribution,They also have relatively large apparent volumes of distribution in excess of 4 L/kg.,Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[l] / [kg],4,96068,DB00557,Hydroxyzine
,2866055,elimination half-life,"In patients with alcohol-related liver disease, the elimination half-life of diphenhydramine was increased from 9 to 15 hours, while in patients with chronic renal disease that of chlorpheniramine was very greatly prolonged.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,9 to 15,96069,DB00557,Hydroxyzine
,16971194,ch,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99830,DB00557,Hydroxyzine
,16971194,run time,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99831,DB00557,Hydroxyzine
,1685361,Serum elimination half-life,"Serum elimination half-life values differ greatly from 1 H1-RA to another, and are 24 h or less for terfenadine, astemizole, loratadine, cetirizine, azelastine and ebastine, and the active metabolites of terfenadine, loratadine and ebastine.",Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685361/),h,24,110704,DB00557,Hydroxyzine
,1685361,serum elimination half-life,"The active metabolite of azelastine (demethylazelastine) has a serum elimination half-life value of about 2 days, while that of astemizole (demethyl-astemizole) has a value of 9.5 days.",Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685361/),d,2,110705,DB00557,Hydroxyzine
,1685361,serum elimination half-life,"The active metabolite of azelastine (demethylazelastine) has a serum elimination half-life value of about 2 days, while that of astemizole (demethyl-astemizole) has a value of 9.5 days.",Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685361/),d,9.5,110706,DB00557,Hydroxyzine
,31386207,flow rate,The chromatography was performed in a gradient elution mode with a 1 mL/min flow rate.,"Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31386207/),[ml] / [min],1,113096,DB00557,Hydroxyzine
,15966463,peak plasma level,A peak plasma level of 286 +/- 68 ng/ml was observed after one hour.,Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ng] / [ml],286,127772,DB00557,Hydroxyzine
,15966463,elimination half-life,"The elimination half-life was 4.1 +/- 0.7 hours, the apparent body clearance 1.05 +/- 0.10 ml/min/kg, and the apparent volume of distribution 0.37 +/- 0.06 l/kg.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),h,4.1,127773,DB00557,Hydroxyzine
,15966463,apparent body clearance,"The elimination half-life was 4.1 +/- 0.7 hours, the apparent body clearance 1.05 +/- 0.10 ml/min/kg, and the apparent volume of distribution 0.37 +/- 0.06 l/kg.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ml] / [kg·min],1.05,127774,DB00557,Hydroxyzine
,15966463,apparent volume of distribution,"The elimination half-life was 4.1 +/- 0.7 hours, the apparent body clearance 1.05 +/- 0.10 ml/min/kg, and the apparent volume of distribution 0.37 +/- 0.06 l/kg.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[l] / [kg],0.37,127775,DB00557,Hydroxyzine
,15966463,Morning trough,"Morning trough values at Days 3-6, and at Day 90 were respectively 78 +/- 30 ng/ml and 110 +/- 86 ng/ml.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ng] / [ml],78,127776,DB00557,Hydroxyzine
,15966463,Morning trough,"Morning trough values at Days 3-6, and at Day 90 were respectively 78 +/- 30 ng/ml and 110 +/- 86 ng/ml.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ng] / [ml],110,127777,DB00557,Hydroxyzine
,7693767,serum elimination half-life,"In contrast to data obtained in healthy adults with normal hepatic function reported in the medical literature, they found that the mean serum elimination half-life value of cetirizine, 13.8 +/- 1.8 hours, was longer, and the mean clearance rate, 0.44 +/- 0.10 mL/min/kg, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),h,13.8,128182,DB00557,Hydroxyzine
,7693767,clearance rate,"In contrast to data obtained in healthy adults with normal hepatic function reported in the medical literature, they found that the mean serum elimination half-life value of cetirizine, 13.8 +/- 1.8 hours, was longer, and the mean clearance rate, 0.44 +/- 0.10 mL/min/kg, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),[ml] / [kg·min],0.44,128183,DB00557,Hydroxyzine
,7693767,peak serum cetirizine concentration,"The mean peak serum cetirizine concentration, 498 +/- 118 ng/mL, was higher, the mean area under the curve, 6438 +/- 1621 ng/mL/hr, was larger, and the mean fraction of the dose excreted as unchanged cetirizine in the urine, .32 +/- .14, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),[ng] / [ml],498,128184,DB00557,Hydroxyzine
,7693767,area under the curve,"The mean peak serum cetirizine concentration, 498 +/- 118 ng/mL, was higher, the mean area under the curve, 6438 +/- 1621 ng/mL/hr, was larger, and the mean fraction of the dose excreted as unchanged cetirizine in the urine, .32 +/- .14, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),[ng] / [h·ml],6438,128185,DB00557,Hydroxyzine
,7693767,fraction of the dose excreted as,"The mean peak serum cetirizine concentration, 498 +/- 118 ng/mL, was higher, the mean area under the curve, 6438 +/- 1621 ng/mL/hr, was larger, and the mean fraction of the dose excreted as unchanged cetirizine in the urine, .32 +/- .14, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),,.32,128186,DB00557,Hydroxyzine
,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,0.9,129595,DB00557,Hydroxyzine
> or =,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,3,129596,DB00557,Hydroxyzine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],0.4,129597,DB00557,Hydroxyzine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],1-1.2,129598,DB00557,Hydroxyzine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],5.4-5.8,129599,DB00557,Hydroxyzine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],49,129600,DB00557,Hydroxyzine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,50-65,129601,DB00557,Hydroxyzine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,33,129602,DB00557,Hydroxyzine
,9084458,peak plasma level,A peak plasma level of 390 +/- 135 ng/ml was observed after 2.0 +/- 1.3 hours.,Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),[ng] / [ml],390,132423,DB00557,Hydroxyzine
,9084458,elimination half-life,"The elimination half-life was 3.1 +/- 1.8 hours, the apparent oral body clearance was 2.13 +/- 1.15 ml/min/kg, and the apparent volume of distribution was 0.44 +/- 0.19 L/kg.",Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),h,3.1,132424,DB00557,Hydroxyzine
,9084458,apparent oral body clearance,"The elimination half-life was 3.1 +/- 1.8 hours, the apparent oral body clearance was 2.13 +/- 1.15 ml/min/kg, and the apparent volume of distribution was 0.44 +/- 0.19 L/kg.",Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),[ml] / [kg·min],2.13,132425,DB00557,Hydroxyzine
,9084458,apparent volume of distribution,"The elimination half-life was 3.1 +/- 1.8 hours, the apparent oral body clearance was 2.13 +/- 1.15 ml/min/kg, and the apparent volume of distribution was 0.44 +/- 0.19 L/kg.",Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),[l] / [kg],0.44,132426,DB00557,Hydroxyzine
,9084458,excretion,The excretion of unchanged cetirizine in six complete urinary collections was 62.7% +/- 13.2% of the administered dose.,Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),%,62.7,132427,DB00557,Hydroxyzine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,5.7,136991,DB00557,Hydroxyzine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,3.9,136992,DB00557,Hydroxyzine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,2.9,136993,DB00557,Hydroxyzine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,1.1,136994,DB00557,Hydroxyzine
,17891537,delta delta QTcSS,"Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,10.5,136995,DB00557,Hydroxyzine
,17891537,delta delta QTcSS,"Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),m,13.4,136996,DB00557,Hydroxyzine
>,10543317,peak plasma concentration,The peak plasma concentration (>500 ng/ml) was rapidly reached in 1 h and the maximal effects were observed later at approximately 6 h.,A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],500,142625,DB00557,Hydroxyzine
,10543317,Ka,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],1.0-1.4,142626,DB00557,Hydroxyzine
,10543317,alpha,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.33-0.69,142627,DB00557,Hydroxyzine
,10543317,terminal half-life,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),h,13.2-13.6,142628,DB00557,Hydroxyzine
,10543317,beta,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.051-0.052,142629,DB00557,Hydroxyzine
,10543317,total clearance,The total clearance was 1.4-1.5 l/h.,A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[l] / [h],1.4-1.5,142630,DB00557,Hydroxyzine
,10543317,concentrations,"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],13,142631,DB00557,Hydroxyzine
,10543317,concentrations,"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],40,142632,DB00557,Hydroxyzine
,10543317,50% of maximal effect (EC50),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],13,142633,DB00557,Hydroxyzine
,10543317,50% of maximal effect (EC50),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],40,142634,DB00557,Hydroxyzine
,10543317,k(in),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.99,142635,DB00557,Hydroxyzine
,10543317,k(in),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.96,142636,DB00557,Hydroxyzine
,26084706,flow rate,"Chromatographic separation was performed on a reverse phase column with an isocratic mobile phase of acetonitrile and 10 mM ammonium formate pH 3.5 (80:20, v/v) at a flow rate of 1.0 mL/min.",Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),[ml] / [min],1.0,145052,DB00557,Hydroxyzine
,26084706,run time,The run time was 3.5 min.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),min,3.5,145053,DB00557,Hydroxyzine
,26084706,m/z,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,389.0,145054,DB00557,Hydroxyzine
,26084706,m/z,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,201.0,145055,DB00557,Hydroxyzine
,26084706,m/z [M+H,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,375.3,145056,DB00557,Hydroxyzine
,26084706,m/z [M+H,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,201.0,145057,DB00557,Hydroxyzine
,26084706,recoveries,"The mean recoveries were 59 and 69% for levocetirizine and hydroxyzine, respectively.",Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),%,59,145058,DB00557,Hydroxyzine
,26084706,recoveries,"The mean recoveries were 59 and 69% for levocetirizine and hydroxyzine, respectively.",Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),%,69,145059,DB00557,Hydroxyzine
,10815716,detection limit,The assay is linear from 10 to 500 ng ml(-1) with a detection limit of 5 ng ml(-1) and a mean recovery of 96.5%.,RP-LC method for the determination of cetirizine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815716/),[ng] / [ml],5,148383,DB00557,Hydroxyzine
,10815716,recovery,The assay is linear from 10 to 500 ng ml(-1) with a detection limit of 5 ng ml(-1) and a mean recovery of 96.5%.,RP-LC method for the determination of cetirizine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815716/),%,96.5,148384,DB00557,Hydroxyzine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,few,153583,DB00557,Hydroxyzine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,9,153584,DB00557,Hydroxyzine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,20 to 25,153585,DB00557,Hydroxyzine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),d,5 to 14,153586,DB00557,Hydroxyzine
,2892445,apparent volumes of distribution,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[l] / [kg],3.4 to 18.5,153587,DB00557,Hydroxyzine
,2892445,total body clearances,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[ml] / [kg·min],4.4 to 32.1,153588,DB00557,Hydroxyzine
,6141198,maximum serum hydroxyzine concentration,"After a single oral dose of hydroxyzine, 0.7 mg/kg (mean dose 39.0 +/- 5.4 mg), the mean maximum serum hydroxyzine concentration of 72.5 +/- 11.1 ng/ml occurred at a mean time of 2.1 +/- 0.4 hr.",The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),[ng] / [ml],72.5,156167,DB00557,Hydroxyzine
,6141198,mean time,"After a single oral dose of hydroxyzine, 0.7 mg/kg (mean dose 39.0 +/- 5.4 mg), the mean maximum serum hydroxyzine concentration of 72.5 +/- 11.1 ng/ml occurred at a mean time of 2.1 +/- 0.4 hr.",The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),h,2.1,156168,DB00557,Hydroxyzine
,6141198,elimination half-life,The mean elimination half-life calculated from the terminal linear portion of the serum hydroxyzine concentration vs. time curve was 20.0 +/- 4.1 hr.,The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),h,20.0,156169,DB00557,Hydroxyzine
,6141198,clearance rate,The mean clearance rate was 9.78 +/- 3.25 ml/min/kg and the mean volume of distribution was 16.0 +/- 3.0 L/kg.,The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),[ml] / [kg·min],9.78,156170,DB00557,Hydroxyzine
,6141198,volume of distribution,The mean clearance rate was 9.78 +/- 3.25 ml/min/kg and the mean volume of distribution was 16.0 +/- 3.0 L/kg.,The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),[l] / [kg],16.0,156171,DB00557,Hydroxyzine
,14520518,wheal area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),mm(2),79.3,158644,DB00557,Hydroxyzine
,14520518,flare area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),cm(2),26.6,158645,DB00557,Hydroxyzine
,2908109,Cmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[ng] / [ml],362,161366,DB00557,Hydroxyzine
,2908109,Tmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,1.30,161367,DB00557,Hydroxyzine
,2908109,terminal half-life,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,11.8,161368,DB00557,Hydroxyzine
,2908109,AUC infinity,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[h·ng] / [ml],4316,161369,DB00557,Hydroxyzine
,2908109,Cmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[ng] / [ml],337,161370,DB00557,Hydroxyzine
,2908109,Tmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,1.12,161371,DB00557,Hydroxyzine
,2908109,terminal half-life,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,10.6,161372,DB00557,Hydroxyzine
,2908109,AUC,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[h·ng] / [ml],3721,161373,DB00557,Hydroxyzine
,20097587,maximum plasma concentration (C(max)),"The estimated maximum plasma concentration (C(max)) and trough plasma concentration of cetirizine were 135 ng/mL and 18 ng/mL, respectively.",Pharmacokinetics and effects of cetirizine in horses with insect bite hypersensitivity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097587/),[ng] / [ml],135,165163,DB00557,Hydroxyzine
,20097587,trough plasma concentration,"The estimated maximum plasma concentration (C(max)) and trough plasma concentration of cetirizine were 135 ng/mL and 18 ng/mL, respectively.",Pharmacokinetics and effects of cetirizine in horses with insect bite hypersensitivity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097587/),[ng] / [ml],18,165164,DB00557,Hydroxyzine
,15025737,intercept,The intercept of the relationship was slightly lower for female children (0.59 vs. 0.77 l h(-1) in male).,Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],0.59,174785,DB00557,Hydroxyzine
,15025737,intercept,The intercept of the relationship was slightly lower for female children (0.59 vs. 0.77 l h(-1) in male).,Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],0.77,174786,DB00557,Hydroxyzine
,15025737,CL/F,"The population estimate of CL/F for an average age of 7 years was 1.61 and 1.43 l h(-1) for male and female children, respectively.",Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],1.61,174787,DB00557,Hydroxyzine
,15025737,CL/F,"The population estimate of CL/F for an average age of 7 years was 1.61 and 1.43 l h(-1) for male and female children, respectively.",Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],1.43,174788,DB00557,Hydroxyzine
,15025737,V/F,The population estimate of V/F for an average age of 7 years was 13.9 l.,Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),l,13.9,174789,DB00557,Hydroxyzine
<,15025737,half-life,"Since V/F increased more rapidly with age than CL/F, a nonlinear increase in half-life was seen, from < 4 h in infants to near the adult value at 12 years of age.",Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),h,4,174790,DB00557,Hydroxyzine
,8477559,plasma elimination half-life,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),h,4.91,183625,DB00557,Hydroxyzine
,8477559,plasma elimination half-life,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),h,8.6,183626,DB00557,Hydroxyzine
,8477559,clearance rate,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),[ml] / [kg·min],1.48,183627,DB00557,Hydroxyzine
,8477559,clearance rate,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),[ml] / [kg·min],0.80,183628,DB00557,Hydroxyzine
,8477559,Urinary excretion,Urinary excretion of unchanged cetirizine was significantly lower in children (p < 0.001; 37.8% +/- 5.2%; n = 5) than in adults (57.7% +/- 11.8%).,A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),%,37.8,183629,DB00557,Hydroxyzine
,8477559,Urinary excretion,Urinary excretion of unchanged cetirizine was significantly lower in children (p < 0.001; 37.8% +/- 5.2%; n = 5) than in adults (57.7% +/- 11.8%).,A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),%,57.7,183630,DB00557,Hydroxyzine
,2572611,peak hydroxyzine levels,Mean peak hydroxyzine levels of 116.5 +/- 60.6 ng/mL occurred at 2.3 +/- 0.7 hours and mean peak cetirizine levels of 500.4 +/- 302.0 ng/mL occurred at 4.8 +/- 2.8 hours.,The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[ng] / [ml],116.5,184584,DB00557,Hydroxyzine
,2572611,peak cetirizine levels,Mean peak hydroxyzine levels of 116.5 +/- 60.6 ng/mL occurred at 2.3 +/- 0.7 hours and mean peak cetirizine levels of 500.4 +/- 302.0 ng/mL occurred at 4.8 +/- 2.8 hours.,The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[ng] / [ml],500.4,184585,DB00557,Hydroxyzine
,2572611,serum elimination half-life,"The mean serum elimination half-life of hydroxyzine was 36.6 +/- 13.1 hours, and the mean serum elimination half-life of cetirizine was 25.0 +/- 8.2 hours.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),h,36.6,184586,DB00557,Hydroxyzine
,2572611,serum elimination half-life,"The mean serum elimination half-life of hydroxyzine was 36.6 +/- 13.1 hours, and the mean serum elimination half-life of cetirizine was 25.0 +/- 8.2 hours.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),h,25.0,184587,DB00557,Hydroxyzine
,2572611,clearance rate,"The mean hydroxyzine clearance rate was 8.65 +/- 7.46 mL/min/kg, and the mean volume of distribution was 22.7 +/- 13.3 L/kg.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[ml] / [kg·min],8.65,184588,DB00557,Hydroxyzine
,2572611,volume of distribution,"The mean hydroxyzine clearance rate was 8.65 +/- 7.46 mL/min/kg, and the mean volume of distribution was 22.7 +/- 13.3 L/kg.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[l] / [kg],22.7,184589,DB00557,Hydroxyzine
,21840269,flow rate,"An aliquot of 150 μl of plasma sample was introduced into the pretreatment column via the auto sampler using mobile phase 1 at a flow rate of 0.5 ml/min, column switching valve being positioned at A.",High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),[ml] / [min],0.5,185335,DB00557,Hydroxyzine
,21840269,flow rate,"Finally, cetirizine, ambroxol and IS were introduced to the separation column by switching valve using mobile phase 2 at a flow rate of 0.4 ml/min.",High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),[ml] / [min],0.4,185336,DB00557,Hydroxyzine
,21840269,total run time,The total run time was 25 min for a sample.,High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),min,25,185337,DB00557,Hydroxyzine
,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,38,187392,DB00557,Hydroxyzine
,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,201,187393,DB00557,Hydroxyzine
>,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,467,187394,DB00557,Hydroxyzine
,18005357,unbound fraction,The unbound fraction was 0.074 for levocetirizine and 0.141 for dextrocetirizine.,"Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),,0.074,190413,DB00557,Hydroxyzine
,18005357,unbound fraction,The unbound fraction was 0.074 for levocetirizine and 0.141 for dextrocetirizine.,"Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),,0.141,190414,DB00557,Hydroxyzine
,18005357,tubular secretion,"The tubular secretion of dextrocetirizine (44.5 mL/min) is higher than that of levocetirizine (23.1 mL/min), which may have consequences for drug interactions at the renal level.","Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),[ml] / [min],44.5,190415,DB00557,Hydroxyzine
,18005357,tubular secretion,"The tubular secretion of dextrocetirizine (44.5 mL/min) is higher than that of levocetirizine (23.1 mL/min), which may have consequences for drug interactions at the renal level.","Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),[ml] / [min],23.1,190416,DB00557,Hydroxyzine
,27085800,total run time,"The total run time was 3.5min and the elution of PZ and HZ occurred at 2.53, and 1.92min, respectively; this was achieved with a mobile phase consisting of 10mM ammonium acetate: acetonitrile (20:80, v/v) at a flow rate of 1.0mL/min on an Ace C18 column with a split ratio of 70:30.",Highly sensitive LC-MS/MS-ESI method for determination of phenelzine in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085800/),min,3.5,192267,DB00557,Hydroxyzine
,27085800,flow rate,"The total run time was 3.5min and the elution of PZ and HZ occurred at 2.53, and 1.92min, respectively; this was achieved with a mobile phase consisting of 10mM ammonium acetate: acetonitrile (20:80, v/v) at a flow rate of 1.0mL/min on an Ace C18 column with a split ratio of 70:30.",Highly sensitive LC-MS/MS-ESI method for determination of phenelzine in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085800/),[ml] / [min],1.0,192268,DB00557,Hydroxyzine
,27085800,split ratio,"The total run time was 3.5min and the elution of PZ and HZ occurred at 2.53, and 1.92min, respectively; this was achieved with a mobile phase consisting of 10mM ammonium acetate: acetonitrile (20:80, v/v) at a flow rate of 1.0mL/min on an Ace C18 column with a split ratio of 70:30.",Highly sensitive LC-MS/MS-ESI method for determination of phenelzine in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085800/),,70,192269,DB00557,Hydroxyzine
,17558437,"partition coefficient, K(p)","The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),,0.06-0.08,193565,DB00557,Hydroxyzine
,17558437,t(max),"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,2-4,193566,DB00557,Hydroxyzine
,17558437,t(max),"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,1-1.5,193567,DB00557,Hydroxyzine
,17558437,terminal half-life,"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,4-5.6,193568,DB00557,Hydroxyzine
,17558437,terminal half-life,"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,2.1-2.8,193569,DB00557,Hydroxyzine
,31996053,tmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),h,0.585,202759,DB00557,Hydroxyzine
,31996053,tmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),h,1.375,202760,DB00557,Hydroxyzine
,31996053,Cmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),[μg] / [ml],0.113,202761,DB00557,Hydroxyzine
,31996053,Cmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),[μg] / [ml],0.0765,202762,DB00557,Hydroxyzine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],475,203570,DB00557,Hydroxyzine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],279,203571,DB00557,Hydroxyzine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],189,203572,DB00557,Hydroxyzine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],118,203573,DB00557,Hydroxyzine
,15889300,"AUC(0-tau,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μgh] / [l],3406,203659,DB00557,Hydroxyzine
,15889300,"AUC(0-tau,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μgh] / [l],4840,203660,DB00557,Hydroxyzine
,15889300,elimination half-life,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),h,7.8,203661,DB00557,Hydroxyzine
,15889300,elimination half-life,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),h,11.9,203662,DB00557,Hydroxyzine
,15889300,"apparent volume of distribution (V(d,ss)/f)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),l,34.7,203663,DB00557,Hydroxyzine
,15889300,"apparent volume of distribution (V(d,ss)/f)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),l,39.8,203664,DB00557,Hydroxyzine
,15889300,apparent total body clearance,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[ml] / [min],49.9,203665,DB00557,Hydroxyzine
,15889300,apparent total body clearance,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[ml] / [min],35.3,203666,DB00557,Hydroxyzine
,15889300,"C(max,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μg] / [l],374,203667,DB00557,Hydroxyzine
,15889300,"C(max,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μg] / [l],408,203668,DB00557,Hydroxyzine
,32149389,half [IC50 ],"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[μM] / [l],237,207864,DB00557,Hydroxyzine
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],1.1,207865,DB00557,Hydroxyzine
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],39,207866,DB00557,Hydroxyzine
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],2.1,207867,DB00557,Hydroxyzine
,19856790,Cmax,"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[μg] / [ml],0.80,209495,DB00557,Hydroxyzine
,19856790,AUC(0-t),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[μg] / [ml],0.80,209496,DB00557,Hydroxyzine
,19856790,AUC(0-infinity),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),h,10.92,209497,DB00557,Hydroxyzine
,19856790,AUC(0-infinity),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[h·μg] / [ml],6.00,209498,DB00557,Hydroxyzine
,19856790,AUC(0-infinity),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[h·μg] / [ml],5.98,209499,DB00557,Hydroxyzine
,19856790,bioavailability,"When the AUC(0-t) values for both formulations for natural log-transformed data were compared, the test formulation showed a bioavailability of 100.9 +/- 7.7%, as compared to the reference formulation.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),%,100.9,209500,DB00557,Hydroxyzine
,26440285,flow rate,"The chromatographic separation was performed using a Chiralpak IE column (2.1 mm×150 mm, 5 μm) with an isocratic elution of CO2/organic modifier (55/45, v/v) at a flow rate of 0.85 mL/min.",Rapid chiral separation of racemic cetirizine in human plasma using subcritical fluid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440285/),[ml] / [min],0.85,211717,DB00557,Hydroxyzine
,1970299,maximum serum cetirizine concentration,"The maximum serum cetirizine concentration and the time to reach that maximum were 285 micrograms.l-1 and 2.0 h, respectively.",Effect of haemodialysis on the pharmacokinetics of cetirizine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),[μg] / [l],285,212623,DB00557,Hydroxyzine
,1970299,time to reach that maximum,"The maximum serum cetirizine concentration and the time to reach that maximum were 285 micrograms.l-1 and 2.0 h, respectively.",Effect of haemodialysis on the pharmacokinetics of cetirizine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),h,2.0,212624,DB00557,Hydroxyzine
,1970299,terminal disposition half-life,The terminal disposition half-life of cetirizine in these patients was 19.3 h.,Effect of haemodialysis on the pharmacokinetics of cetirizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),h,19.3,212625,DB00557,Hydroxyzine
,1970299,clearance,The haemodialysis clearance of cetirizine was 14.0 ml. min-1.,Effect of haemodialysis on the pharmacokinetics of cetirizine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),[ml] / [min],14.0,212626,DB00557,Hydroxyzine
,18447800,terminal half-life,"Mean +/- SD terminal half-life was 10.06 +/- 4.05 hours, and mean peak plasma concentration was 3.30 +/- 1.55 microg/mL.",Pharmacokinetics of cetirizine in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),h,10.06,215041,DB00557,Hydroxyzine
,18447800,peak plasma concentration,"Mean +/- SD terminal half-life was 10.06 +/- 4.05 hours, and mean peak plasma concentration was 3.30 +/- 1.55 microg/mL.",Pharmacokinetics of cetirizine in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[μg] / [ml],3.30,215042,DB00557,Hydroxyzine
,18447800,volume of distribution,"Mean volume of distribution and clearance (per fraction absorbed) were 0.24 +/- 0.09 L/kg and 0.30 +/- 0.09 mL/kg/min, respectively.",Pharmacokinetics of cetirizine in healthy cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[l] / [kg],0.24,215043,DB00557,Hydroxyzine
,18447800,clearance (per fraction absorbed),"Mean volume of distribution and clearance (per fraction absorbed) were 0.24 +/- 0.09 L/kg and 0.30 +/- 0.09 mL/kg/min, respectively.",Pharmacokinetics of cetirizine in healthy cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[ml] / [kg·min],0.30,215044,DB00557,Hydroxyzine
,18447800,Protein binding,Protein binding was approximately 88%.,Pharmacokinetics of cetirizine in healthy cats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),%,88,215045,DB00557,Hydroxyzine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,5.2,217311,DB00557,Hydroxyzine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,8.3,217312,DB00557,Hydroxyzine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,9.6,217313,DB00557,Hydroxyzine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,11.6,217314,DB00557,Hydroxyzine
less,23106955,total run time,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,15,217315,DB00557,Hydroxyzine
,10836747,retention times,"(+)-Cetirizine, (-)-cetirizine and the internal standard were eluted at retention times of 12, 16, and 32 mins, respectively.",Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),min,12,218722,DB00557,Hydroxyzine
,10836747,retention times,"(+)-Cetirizine, (-)-cetirizine and the internal standard were eluted at retention times of 12, 16, and 32 mins, respectively.",Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),min,16,218723,DB00557,Hydroxyzine
,10836747,retention times,"(+)-Cetirizine, (-)-cetirizine and the internal standard were eluted at retention times of 12, 16, and 32 mins, respectively.",Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),min,32,218724,DB00557,Hydroxyzine
,10836747,detection limit,The detection limit for cetirizine enantiomers was 400 ng/ml of urine.,Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),[ng] / [ml],400,218725,DB00557,Hydroxyzine
,2884246,serum half-life,"The mean serum half-life value on day 30, 60, and 120 was significantly longer (p less than 0.05) than that of 2.4 +/- 0.3 hours obtained on day 1.",The effect of chronic administration of hydroxyzine on hydroxyzine pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884246/),h,2.4,219069,DB00557,Hydroxyzine
,2884246,clearance,"The mean clearance values obtained on days 30, 60, 90, 120, and 150 were significantly slower (p less than 0.05) than the value of 25.12 +/- 4.13 ml/min/kg obtained on day 1 but were not significantly different from each other.",The effect of chronic administration of hydroxyzine on hydroxyzine pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884246/),[ml] / [kg·min],25.12,219070,DB00557,Hydroxyzine
,2884246,apparent volume of distribution,"The mean apparent volume of distribution values obtained on days 30, 60, 90, 120, and 150 did not differ significantly from the value of 5.0 +/- 1.5 L/kg obtained on day 1.",The effect of chronic administration of hydroxyzine on hydroxyzine pharmacokinetics in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884246/),[l] / [kg],5.0,219071,DB00557,Hydroxyzine
,12083980,maximum concentration,"Concentration-time profiles for cetirizine in serum and tear fluid were similar, although the mean maximum concentration in tear fluid was reached later than in serum (90 and 30 min, respectively).",Pharmacokinetics of cetirizine in tear fluid after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083980/),min,90,223450,DB00557,Hydroxyzine
,12083980,maximum concentration,"Concentration-time profiles for cetirizine in serum and tear fluid were similar, although the mean maximum concentration in tear fluid was reached later than in serum (90 and 30 min, respectively).",Pharmacokinetics of cetirizine in tear fluid after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083980/),min,30,223451,DB00557,Hydroxyzine
,17472650,terminal half-life,"After oral administration of cetirizine at 0.2 mg/kg bw, the mean terminal half-life was 3.4 h (range 2.9-3.7 h) and the maximal plasma concentration 132 ng/mL (101-196 ng/mL).",Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),h,3.4,226145,DB00557,Hydroxyzine
,17472650,maximal plasma concentration,"After oral administration of cetirizine at 0.2 mg/kg bw, the mean terminal half-life was 3.4 h (range 2.9-3.7 h) and the maximal plasma concentration 132 ng/mL (101-196 ng/mL).",Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),[ng] / [ml],132,226146,DB00557,Hydroxyzine
,17472650,time to reach maximal plasma concentration,The time to reach maximal plasma concentration was 0.7 h (0.5-0.8 h).,Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),h,0.7,226147,DB00557,Hydroxyzine
,26966353,relative bioavailability,"In addition, the relative bioavailability of the optimized formulation was 165.5% with respect to the marketed CTZ tablets indicating a significant enhancement of CTZ bioavailability.",Maximizing the encapsulation efficiency and the bioavailability of controlled-release cetirizine microspheres using Draper-Lin small composite design. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966353/),%,165.5,226548,DB00557,Hydroxyzine
,24856961,AUC0-∞,"The pharmacokinetic data of optimized CTZ microspheres showed prolonged tmax, decreased Cmax and AUC0-∞ value of 3309 ± 211 ng h/ml indicating improved relative bioavailability by 169.4% compared with marketed tablets.",Statistical optimization of controlled release microspheres containing cetirizine hydrochloride as a model for water soluble drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24856961/),[h·ng] / [ml],3309,234171,DB00557,Hydroxyzine
,24856961,relative bioavailability,"The pharmacokinetic data of optimized CTZ microspheres showed prolonged tmax, decreased Cmax and AUC0-∞ value of 3309 ± 211 ng h/ml indicating improved relative bioavailability by 169.4% compared with marketed tablets.",Statistical optimization of controlled release microspheres containing cetirizine hydrochloride as a model for water soluble drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24856961/),%,169.4,234172,DB00557,Hydroxyzine
,10805062,area under the concentration-time curve (AUC)0-24,"Following the administration of 4 mg emedastine q.d., mean area under the concentration-time curve (AUC)0-24 values of 34.49 +/- 24.07 ng h ml(-1) and 47.05 +/- 36.12 ng h ml(-1) were attained on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],34.49,239295,DB00557,Hydroxyzine
,10805062,area under the concentration-time curve (AUC)0-24,"Following the administration of 4 mg emedastine q.d., mean area under the concentration-time curve (AUC)0-24 values of 34.49 +/- 24.07 ng h ml(-1) and 47.05 +/- 36.12 ng h ml(-1) were attained on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],47.05,239296,DB00557,Hydroxyzine
,10805062,AUC0-24,"Following the administration of emedastine (2 mg b.i.d.) mean AUC0-24 values were 29.75 +/- 19.92 ng h ml(-1) and 46.13 +/- 38.50 ng h ml(-1) on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],29.75,239297,DB00557,Hydroxyzine
,10805062,AUC0-24,"Following the administration of emedastine (2 mg b.i.d.) mean AUC0-24 values were 29.75 +/- 19.92 ng h ml(-1) and 46.13 +/- 38.50 ng h ml(-1) on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],46.13,239298,DB00557,Hydroxyzine
,16713697,flow-rate,"Chromatographic separation was performed on a Hypurity C18 column (Thermo Hypersil-Keystone 2.1 mm x 150 mm, 5 microm, USA), The mobile phase was composed of 65% methanol and 35% water (contained 0.1% formic acid, 10 mM ammonium formate), which was run with a flow-rate of 0.2 ml/min at 40 degrees C.",Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ml] / [min],0.2,241323,DB00557,Hydroxyzine
,16713697,limit of detection,The limit of detection for pseudoephedrine and cetirizine each was 5 ng/ml.,Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ng] / [ml],5,241324,DB00557,Hydroxyzine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),[ng] / [ml],427.6,244555,DB00557,Hydroxyzine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),[ng] / [ml],144.2,244556,DB00557,Hydroxyzine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,1.4,244557,DB00557,Hydroxyzine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),[ng] / [ml],978.4,244558,DB00557,Hydroxyzine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,0.8,244559,DB00557,Hydroxyzine
,2571627,serum-elimination half-life,"The dose-independent serum-elimination half-life of cetirizine was 7.1 +/- 1.6 hours after cetirizine, 5 mg, and 6.9 +/- 1.6 hours after cetirizine, 10 mg.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,7.1,244560,DB00557,Hydroxyzine
,2571627,serum-elimination half-life,"The dose-independent serum-elimination half-life of cetirizine was 7.1 +/- 1.6 hours after cetirizine, 5 mg, and 6.9 +/- 1.6 hours after cetirizine, 10 mg.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,6.9,244561,DB00557,Hydroxyzine
,2571627,Urinary excretion,"Urinary excretion of unchanged cetirizine during 24 hours after the initial dose of cetirizine, 5 mg, was 40 +/- 15%, and after cetirizine, 10 mg, it was 39 +/- 14%.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),%,40,244562,DB00557,Hydroxyzine
,2571627,Urinary excretion,"Urinary excretion of unchanged cetirizine during 24 hours after the initial dose of cetirizine, 5 mg, was 40 +/- 15%, and after cetirizine, 10 mg, it was 39 +/- 14%.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),%,39,244563,DB00557,Hydroxyzine
,2892446,elimination half-life,"We found that the elimination half-life of cetirizine was prolonged in patients with mild and moderate renal insufficiency, compared with age-matched individuals with normal renal function (19.0 +/- 3.3 and 20.9 +/- 4.4 hours, vs 7.4 +/- 3.0 hours, respectively).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),h,19.0,250441,DB00557,Hydroxyzine
,2892446,elimination half-life,"We found that the elimination half-life of cetirizine was prolonged in patients with mild and moderate renal insufficiency, compared with age-matched individuals with normal renal function (19.0 +/- 3.3 and 20.9 +/- 4.4 hours, vs 7.4 +/- 3.0 hours, respectively).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),h,20.9,250442,DB00557,Hydroxyzine
,2892446,elimination half-life,"We found that the elimination half-life of cetirizine was prolonged in patients with mild and moderate renal insufficiency, compared with age-matched individuals with normal renal function (19.0 +/- 3.3 and 20.9 +/- 4.4 hours, vs 7.4 +/- 3.0 hours, respectively).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),h,7.4,250443,DB00557,Hydroxyzine
,2892446,apparent steady-state volume of distribution,"However, the mean apparent steady-state volume of distribution did not differ significantly between these subject groups (range 0.41 to 0.47 L/kg).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),[l] / [kg],0.41 to 0.47,250444,DB00557,Hydroxyzine
,18371719,accumulation time,"The optimized procedural conditions were: frequency=120Hz, scan increment=10mV, pulse-amplitude=25mV, accumulation potential=-0.3V, accumulation time=90-300s and a Britton-Robinson universal buffer of pH 4 as a supporting electrolyte.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),s,90-300,250920,DB00557,Hydroxyzine
,18371719,recoveries,"Mean recoveries of 100.5+/-0.71 and 98.6+/-1.12% (n=5) were achieved for assay of hydroxyzine in Atarax 10 and 25mg dosage forms, respectively.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),%,100.5,250921,DB00557,Hydroxyzine
,18371719,recoveries,"Mean recoveries of 100.5+/-0.71 and 98.6+/-1.12% (n=5) were achieved for assay of hydroxyzine in Atarax 10 and 25mg dosage forms, respectively.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),%,98.6,250922,DB00557,Hydroxyzine
,18371719,Limit of detection,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[moll],1.5x10(-8),250923,DB00557,Hydroxyzine
,18371719,Limit of detection,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[ngml],5.624,250924,DB00557,Hydroxyzine
,18371719,limit of quantitation,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[moll],5.0x10(-8),250925,DB00557,Hydroxyzine
,18371719,limit of quantitation,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[ngml],18.746,250926,DB00557,Hydroxyzine
,18371719,recovery,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),%,98.4,250927,DB00557,Hydroxyzine
,27121892,serum elimination half-life,The serum elimination half-life was 5.83 ± 0.841 h.,Elimination of cetirizine following administration of multiple doses to exercised thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121892/),h,5.83,251351,DB00557,Hydroxyzine
,11758635,blood-to-plasma ratio,"Levocetirizine and/or its metabolites were not, or only very poorly, associated with blood cells, as the blood-to-plasma ratio was 0.51 to 0.68.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),,0.51 to 0.68,254748,DB00557,Hydroxyzine
,11758635,apparent volume of distribution (Vz/F),The mean apparent volume of distribution (Vz/F) was 26.9 1 (0.3 l/kg) indicating that the distribution of levocetirizine is restrictive.,"Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),1,26.9,254749,DB00557,Hydroxyzine
,11758635,protein binding,The protein binding of radiolabelled levocetirizine was 96.1% l h after administration.,"Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%·h·l,96.1,254750,DB00557,Hydroxyzine
,11758635,protein binding,"In vitro, at concentrations ranging from 0.2 microg/ml to 1 microg/ml, the protein binding was 94.8% to 95.0%.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%,94.8,254751,DB00557,Hydroxyzine
,11758635,protein binding,"In vitro, at concentrations ranging from 0.2 microg/ml to 1 microg/ml, the protein binding was 94.8% to 95.0%.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%,95.0,254752,DB00557,Hydroxyzine
,8799876,recovery,The proposed method had a recovery of 98% and the lowest amount of cetirizine that could be detected was 50 ng.,High-performance thin-layer chromatography for the determination of cetirizine in human plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799876/),%,98,258560,DB00557,Hydroxyzine
,7582385,peak plasma level (Cmax),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[μg] / [l],607,261207,DB00557,Hydroxyzine
,7582385,tmax,"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,1.93,261208,DB00557,Hydroxyzine
,7582385,elimination half-life (t1/2),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,5.55,261209,DB00557,Hydroxyzine
,7582385,area under the plasma concentration time curve (AUC0-infinity),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),μg,"4,772.1",261210,DB00557,Hydroxyzine
,7582385,mean residence time (MRT),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,8.13,261211,DB00557,Hydroxyzine
,7582385,apparent plasma clearance (Cl/f),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[ml] / [kg·min],1.27,261212,DB00557,Hydroxyzine
,7582385,apparent volume of distribution (Vz/f),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[l] / [kg],0.60,261213,DB00557,Hydroxyzine
,7582385,Urinary recovery,Urinary recovery was 38.4 +/- 9.9% (n = 4) of the dose.,Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),%,38.4,261214,DB00557,Hydroxyzine
,7582385,Renal clearance,Renal clearance was 0.42 +/- 0.10 ml.min-1.kg-1 (n = 6).,Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[ml] / [kg·min],0.42,261215,DB00557,Hydroxyzine
,11564134,apparent volume of distribution,"When comparing the pharmacokinetic characteristics of levocetirizine and the distomer, the apparent volume of distribution of the eutomer is significantly smaller than that of the distomer (0.41 and 0.60 L/kg, respectively).","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[l] / [kg],0.41,261882,DB00557,Hydroxyzine
,11564134,apparent volume of distribution,"When comparing the pharmacokinetic characteristics of levocetirizine and the distomer, the apparent volume of distribution of the eutomer is significantly smaller than that of the distomer (0.41 and 0.60 L/kg, respectively).","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[l] / [kg],0.60,261883,DB00557,Hydroxyzine
,11564134,non-renal clearance,"Moreover the non-renal clearance of levocetirizine is also significantly lower than that of the distomer (9.70 and 28.70 mL/min, respectively), which constitutes an additional positive aspect particularly as far as metabolism-based drug interactions are concerned.","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[ml] / [min],9.70,261884,DB00557,Hydroxyzine
,11564134,non-renal clearance,"Moreover the non-renal clearance of levocetirizine is also significantly lower than that of the distomer (9.70 and 28.70 mL/min, respectively), which constitutes an additional positive aspect particularly as far as metabolism-based drug interactions are concerned.","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[ml] / [min],28.70,261885,DB00557,Hydroxyzine
,15760103,area under the curve [AUC],Plasma cetirizine concentrations from MLV (area under the curve [AUC] of 221.2 +/- 42.3 ng x hr/mL) were lower than from GB (AUC of 248.3 +/- 34.6 ng.hr/mL).,Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15760103/),[h·ng] / [ml],221.2,264517,DB00557,Hydroxyzine
,15760103,AUC,Plasma cetirizine concentrations from MLV (area under the curve [AUC] of 221.2 +/- 42.3 ng x hr/mL) were lower than from GB (AUC of 248.3 +/- 34.6 ng.hr/mL).,Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15760103/),[h·ng] / [ml],248.3,264518,DB00557,Hydroxyzine
,2562944,serum elimination t1/2,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),h,29.3,269880,DB00557,Hydroxyzine
,2562944,volume of distribution,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),[l] / [kg],22.5,269881,DB00557,Hydroxyzine
,2562944,clearance rate,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),[ml] / [kg·min],9.6,269882,DB00557,Hydroxyzine
,2562944,AUC,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),[h·ng] / [ml],1383.1,269883,DB00557,Hydroxyzine
,2562944,serum elimination t1/2,"The mean serum elimination t1/2 of cetirizine, the active metabolite of hydroxyzine generated in vivo, was 24.8 +/- 7.7 hours, not significantly different from that of the parent compound (p = 0.05).",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),h,24.8,269884,DB00557,Hydroxyzine
,31490561,terminal half-life,"The terminal half-life was 7.41 and 7.13 hr for hydroxyzine and cetirizine, respectively.",Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490561/),h,7.41,271230,DB00557,Hydroxyzine
,31490561,terminal half-life,"The terminal half-life was 7.41 and 7.13 hr for hydroxyzine and cetirizine, respectively.",Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490561/),h,7.13,271231,DB00557,Hydroxyzine
,18980631,systemic availability,The mean systemic availability of oral hydroxyzine was 72%.,Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,72,272329,DB00557,Hydroxyzine
,18980631,peak concentration,"After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),[μg] / [ml],2.2,272330,DB00557,Hydroxyzine
,18980631,peak concentration,"After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),[μg] / [ml],0.16,272331,DB00557,Hydroxyzine
,18980631,terminal half-life,The terminal half-life for cetirizine varied between 10 and 11 h after intravenous and oral administration of hydroxyzine.,Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),h,10 and 11,272332,DB00557,Hydroxyzine
,18980631,Maximum inhibition,"Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,82,272333,DB00557,Hydroxyzine
,18980631,Maximum inhibition,"Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,69,272334,DB00557,Hydroxyzine
